Literally gouging

In conclusion, we found no evidence of increased risks of mortality, myocardial infarction, bleeding, or stroke,” their research paper said.The other danger to using Avastin, however, has attracted a lot of publicity in recent years.The fact that the drug needs to be repackaged into smaller doses introduces an element of risk because it opens the possibility that the drug could be tainted during the repackaging process. (Genentech says because the FDA has not approved it for use in the eye, the company cannot legally distribute Avastin in doses appropriate for the eye.Indeed, in three cases that made the news — in South Florida, Nashville and Los Angeles — just such a problem has arisen. Several patients reportedly suffered vision loss as a result.“I’ve never used Avastin because of the potential for contamination,” Warren L. Herron Jr., a Pensacola, Fla., ophthalmologist, said after a morning in which he did 11 eye injections. “Is it a rare thing? Yes, it’s a rare thing. But I can’t stand the idea of ever telling my patients that they can no longer see because I used a tainted drug.“Besides,” he said, “I don’t think the extra money being spent for Lucentis is totally wasted because it’s going into research and development.”But as Herron noted, the likelihood of contamination is negligible. Globally, hundreds of thousands of injections are doled out every year without trouble, making the risk of contamination in repackaging smaller than the risks...
Source: PharmaGossip - Category: Pharma Commentators Authors: Source Type: blogs